Skip to main content
. 2021 Dec 12;12(1):15. doi: 10.1007/s13205-021-03076-0

Table 3.

Live attenuate Vaccine candidates in development for SARS-CoV-2 virus

Live Attenuated Vaccine candidates (Source: WHO as per 15th October 2021)
Candidate Dose Schedule Route of Administration Phase Developer
COVI-VAC 1–2

Day 0 or

Day 0 + 28

Intranasal

Phase 1

NCT04619628

Codagenix/Serum Institute of India
MV-014–212, expresses the spike (S) protein 1 Day 0 Intranasal

Phase 1

NCT04798001

Meissa Vaccines, Inc